Ataraxis Breast NEO
About this test
Before starting treatment, determine the response to neoadjuvant therapy.
The Ataraxis® Breast NEO test predicts, using artificial intelligence (AI), the probability of achieving a complete response to neoadjuvant therapy across all molecular subtypes of breast cancer.
The test material is an H&E slide (preparation) from a biopsy. A copy of the histopathology report must be delivered to the laboratory together with the material.
When ordering the test, use the code: ATARAXIS
How the test works
-
1
Order online
No referral needed. You order online.
-
2
Send the material
You send the material (e.g. a histopathology slide) to the laboratory.
-
3
Result
Available in 10 working days from sample registration in laboratory, online.
Frequently asked questions
Who is this test for?
Ataraxis Breast NEO assesses the probability of achieving a pathological complete response (pCR) after preoperative treatment in patients with stage I–III invasive breast cancer, regardless of molecular subtype: the test applies both to tumours with hormone receptor expression (HR+) and without it (HR-), both HER2-positive and HER2-negative, including triple-negative breast cancers (TNBC), and regardless of lymph node involvement and menopausal status. In patients with clinically involved lymph nodes (cN+), the report additionally includes the estimated probability of pCR in the axillary nodes.
How long does the Ataraxis Breast NEO test take?
The result is usually available within 10 working days from sample registration in laboratory.
Do I need a referral?
No. You can order this genetic test online without a referral.
How much does the test cost?
The price of the test is 920 EUR.
Which Ataraxis test should I choose?
The right test depends on the moment of treatment and the molecular subtype of the tumour.
Ataraxis Breast RISK assesses the risk of recurrence in patients with stage I–III invasive breast cancer, regardless of molecular subtype. It answers the question of how high the risk of disease recurrence is within 5 years.
Ataraxis Breast CTX assesses the individual benefit of adding adjuvant chemotherapy to hormone therapy. It is intended exclusively for tumours with hormone receptor expression and without HER2 overexpression (HR+ HER2-), and therefore does not apply to HER2-positive or triple-negative cancers. It answers the question of whether chemotherapy is worth adding to hormone therapy.
Ataraxis Breast NEO assesses the probability of achieving a pathological complete response (pCR) after preoperative treatment, regardless of molecular subtype, lymph node involvement and menopausal status. It is performed on a core-needle biopsy specimen taken at diagnosis, i.e. before surgery. It answers the question of whether treatment preceding surgery has a chance of completely eradicating the tumour.
If your tumour belongs to the HR+ HER2- subtype, the Breast CTX test should be ordered. The same risk of recurrence does not mean the same benefit from chemotherapy; about one quarter of patients classified as high risk derive little benefit from chemotherapy.
Which test is appropriate in a given situation is decided by the treating physician based on disease stage, tumour receptor status and the planned treatment. The test result does not replace medical advice.
Ready to order Ataraxis Breast NEO
Order online — no referral needed.